New hope for rare leukemia: oral drug shows promise in early trial
NCT ID NCT05141682
First seen Nov 10, 2025 · Last updated Jun 21, 2026 · Updated 35 times
Summary
This phase I/II trial tests an oral chemotherapy drug called azacitidine (CC-486) in 11 adults with a rare type of leukemia (T-LGLL) that has come back or not responded to prior treatment. The study aims to find the best dose and see if the drug can shrink or control the cancer. Researchers will also track how long any response lasts and monitor side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-CELL LARGE GRANULAR LYMPHOCYTE LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
University of Virginia
Charlottesville, Virginia, 22908, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
oral azacitidine (CC-486)
What this could lead to
If it works, this could offer a new treatment option for patients with T-LGLL leukemia that has not responded to standard therapies.
What could go wrong
This is a small, early-phase trial with only 11 participants, so results may not apply broadly. The drug may cause side effects or fail to control the disease.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.